Allogene Therapeutics, Inc.
ALLO · NASDAQ
Market closed$1.79$0.00 (0.00%)After hours $1.80 · +0.56%
Key statistics
Previous close$1.79
Open$1.74
Day high$1.83
Day low$1.74
52-week high$4.46
52-week low$0.980000
Market cap436.53M
Volume4.92M
Average volume8.35M
P/E ratio-2.32
Forward P/E—
EPS-0.77
Dividend yield0.00%
Market context
Why it moved
ALLO edged slightly higher following the publication of Phase 1 results for ALLO-316 in the Journal of Clinical Oncology, highlighting durable remissions in kidney cancer patients treated with Allogene's allogeneic CAR T cell therapy, reinforcing investor confidence in the company's pipeline.
What is happening
Recent company-specific developments and publisher coverage.
The Clinical Trial Vanguard · July 16, 2026Allogene’s ALLO-316 Achieves 31% Response Rate in Advanced Renal Cell CarcinomaGlobeNewswire · July 15, 2026Allogene Therapeutics Announces Journal of ClinicalInvesting.com · July 15, 2026Allogene reports 31% response rate in renal cancer trialSeeking Alpha · July 4, 2026Allogene Therapeutics: High-Upside Bet On The Next Wave Of CAR-T Innovation (NASDAQ:ALLO)Moomoo · May 29, 2026Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10GlobeNewswire · May 13, 2026Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business UpdateInvesting.com · April 10, 2026Jefferies initiates Allogene stock coverage with buy rating on cancer therapy potentialQuiver Quantitative · April 10, 2026Allogene Therapeutics to Host Conference Call on Interim Futility Analysis from ALPHA3 Trial of Cemacabtagene Ansegedleucel in LBCL Benzinga · July 15, 2026Allogene Therapeutics Publishes Data From Phase 1 TRAVERSE Trial Of ALLO-316 In Advanced Or Metastatic Renal Cell Carcinoma; Trial Shows 31% Confirmed Response Rate With Recommended Phase 2 Regimen; Robust Expansion And Tumor Infiltration Seen Mt Newswire · May 28, 2026Allogene Therapeutics CEO David Chang Steps Down Benzinga · May 13, 2026Allogene Therapeutics Q1 2026 Earnings Call Transcript Mt Newswire · May 13, 2026Allogene Therapeutics Q1 Net Loss Narrows Benzinga · May 13, 2026Allogene Therapeutics Enters Termination Agreement With Overland Therapeutics On May 12, 2026; Terminates Exclusive License Agreement With Overland Therapeutics Effective May 12, 2026; No Termination Payments Made In Connection With Termination Agreement; To Hold About 3% Of Overland Equity After Surrendering Portion For No Consideration Mt Newswire · May 13, 2026Earnings Flash (ALLO) Allogene Therapeutics Posts Q1 Loss $0.18, vs. FactSet Est of $0.19 Loss Benzinga · May 13, 2026Allogene Therapeutics Q1 EPS $(0.18) Beats $(0.19) Estimate Mt Newswire · April 21, 2026Allogene Therapeutics Cleared to Expand B-Cell Lymphoma Treatment Trial in South Korea, Australia